希罗达联合多西紫杉醇治疗晚期乳腺癌60例临床观察

目的观察希罗达联合多西紫杉醇治疗晚期乳腺癌的疗效及毒副反应。方法将120例晚期乳腺癌患者随机分为两组，联合组（n=60例）采用希罗达950mg／m2，每天2次口服，连用14d。多西紫杉醇37．5mg／m2，静脉滴注，第1、8天。对照组（n=60例）采用多西紫杉醇50mg／m2，静脉滴入，第1、8天。21d为1个周期，治疗2个周期后评价疗效及不良反应。结果联合组有效率（CR＋PR）为58．33％，中位生存时间为15．2个月，主要不良反应为手足综合征、骨髓抑制、脱发和消化道毒性。对照组有效率（CR＋PR）为41．67％，中位生存时间为11．8个月。对照组不良反应主要为骨髓抑制、消化道毒性、发热、肌痛、关节痛等。两组有效率和生存期比较，差异均有统计学意义（P〈0．05）。结论希罗达联合多西紫杉醇作为二线方案治疗晚期乳腺癌的疗效确切，优于单一多西紫杉醇治疗，且不良反应轻，可以作为紫杉类或蒽环类药物治疗失败的晚期乳腺癌的解救方案。

Clinical observation on advanced breast cancer treated with xeloda and docetaxel

Objective To observe the efficacy and toxicity of xeloda combined with docetaxel in treating 60 patients with advanced breast cancer. Methods 120 patients with advanced breast cancer were randomly divided into two groups. In the combining group, xeloda was given 950 mg/m： twice a day for 14 days, and docetaxel was given 37.5 mg/m2 during the 1st , 8th day. The chemotherapy repeated every three weeks. Efficacy and toxicity were reviewed after two cycles of chemotherapy. Results In the combining group, the effective rate was 52.00% and median survival time was 15.2 months. Most common toxicities were hand- foot syndrome, myelosuppression, baldness and gastrointestinal toxicities, etc. In the control group, the effective rate was 24.00% and median survival time was 11.8 months. Most common toxicities were myelosuppression, gastrointestinal toxicities, fever, myalgia and arthralgia etc. Conclusion Xeloda combined with Docetaxel as second - line chemotherapy was effective in treating advanced breast cancer. The overall survival is significantly prolonged, toxicities were mild and acceptable. This regimen could be used in the patients after failure from treatment by taxol and anthraeycline.